Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

102.07USD
20 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$102.07
Open
$98.40
Day's High
$105.77
Day's Low
$96.79
Volume
10,311,447
Avg. Vol
1,290,881
52-wk High
$165.87
52-wk Low
$95.21

Select another date:

Tue, Aug 20 2019

Sarepta shares sink 14% after shock FDA rejection

Shares of Sarepta Therapeutics Inc plunged 14% on Tuesday after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

UPDATE 2-Sarepta shares sink 14% after shock FDA rejection

Aug 20 Shares of Sarepta Therapeutics Inc plunged 14% on Tuesday after the U.S. health regulator, in an unexpected move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

Sarepta shares sink 17% after shock FDA rejection

Aug 20 Shares of Sarepta Therapeutics Inc plummeted 17% on Tuesday after the U.S. health regulator, in a surprise move, declined to approve the drugmaker's newest treatment for a muscle-wasting disorder that mainly affects young boys.

FDA declines to approve Sarepta's second Duchenne treatment

Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

UPDATE 2-U.S. FDA declines to approve Sarepta's second Duchenne treatment

Aug 19 Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

U.S. FDA declines to approve Sarepta's second Duchenne drug

Aug 19 The U.S. Food and Drug Administration declined to approve Sarepta Therapeutics Inc's newest treatment for Duchenne muscular dystrophy (DMD), a rare muscle-wasting disorder that mainly affects boys, the company said on Monday.

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD).

UPDATE 1-Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD) was reported to have developed a serious illness.

Patient in Sarepta gene therapy trial develops serious illness; shares plunge

Aug 8 Shares of Sarepta Therapeutics Inc plunged 12% after a notice from the U.S. health agency showed a patient in an ongoing study of the company's gene therapy for Duchenne muscular dystrophy was reported to have developed a serious illness.

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .

Select another date: